ABVX vs UNH

Abivax SA continues to exhibit significant 10x growth potential, primarily de-risked by obefazimod's positive DSMB review in its Phase 3 UC trial (90% complete, topline late Q2 2026). The substantial €530.4M cash position, secured through a recent offering, provides a runway to Q4 2027, mitigating immediate financial risk. The drug's differentiated oral, first-in-class STAT1 inhibitor profile stil...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...